Posted by Oscar (Syracuse, New York, Usa) on 02/14/2013
An important newly published study from the University of Naples shows vitamin B12 and vitamin D to be of great benefit for HCV infectees. This same study states taking vitamin E enhances the HCV viruses' ability to replicate and should NOT be used as a supplement. Again, do NOT use vitamin E supplements while treating a hepatitis C infection.
Some highlights from this study here:
Significance of this study
What is already known on this subject?
< Less than 50% of individuals infected with hepatitis C virus (HCV) genotype 1 clear the infection after treatment with the combination of
pegylated interferon-a and ribavirin.
< The non-structural 3/4A protease inhibitors boceprevir and telaprevir significantly improve the sustained viral response (SVR) rate in
patients with chronic HCV genotype 1 infection naiive to treatment. However, several questions remain about the applicability of these directacting antiviral agents in 'real-life' conditions.
< In vitro, vitamin B12 inhibits HCV translation by directly interacting with the internal ribosomal entry site of HCV-RNA.
What are the new findings?
< In patients with chronic HCV infection naiive to antiviral therapy, vitamin B12 supplementation improves the overall rate of SVR to pegylated interferon-a and ribavirin by 34%. The effect seems to be particularly pronounced in difficultto- treat patientsdnamely, those infected with HCV genotype 1 and with a high baseline viral load.
How might it impact on clinical practice in the foreseeable future?
< The new-generation HCV antiviral drugs, such as direct-acting agents, need careful monitoring and stringent futility rules to prevent the
emergence of multiresistant HCV strains and to avoid overtreatment of patients. Until eligibility criteria are well established, the standard
of care +B12 combination is a safe and inexpensive alternative to improve the rate of SVR in difficult-to-treat patients. This strategy
would be especially useful in those countries where, owing to limited economic means, the new-generation antiviral therapies cannot be
given in routine clinical practice.
A link to this very important study in its entirety here: